| pubmed-article:2846327 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0040778 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0205245 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:2846327 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:2846327 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2846327 | pubmed:dateCreated | 1988-12-1 | lld:pubmed |
| pubmed-article:2846327 | pubmed:abstractText | The effects of chronic (28 d Alzet 2002 osmotic mini-pumps) administration of antidepressant drugs on the functional sensitivity of alpha 2-adrenoceptors and on monoamine oxidase activity has been assessed. Tranylcypromine, 4-fluorotranylcypromine and clorgyline (0.5-1.0 mg kg-1) induced a decrease in the motor-suppressant effects of clonidine (50 micrograms kg-1) observed at 9-10 and 23-24 days of drug administration. These effects were associated with marked decreases in type A (clorgyline) or type A and B monoamine oxidase activity (tranylcypromine and 4-fluorotranylcypromine). The results indicate that alpha 2-adrenoceptor down-regulation is an early emergent feature of adaptive changes in noradrenaline systems induced by prolonged exposure to tranylcypromine. | lld:pubmed |
| pubmed-article:2846327 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2846327 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2846327 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2846327 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2846327 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2846327 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2846327 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2846327 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2846327 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2846327 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:2846327 | pubmed:author | pubmed-author:RaoT STS | lld:pubmed |
| pubmed-article:2846327 | pubmed:author | pubmed-author:CouttsR TRT | lld:pubmed |
| pubmed-article:2846327 | pubmed:author | pubmed-author:BakerG BGB | lld:pubmed |
| pubmed-article:2846327 | pubmed:author | pubmed-author:NazaraliA JAJ | lld:pubmed |
| pubmed-article:2846327 | pubmed:author | pubmed-author:GreenshawA... | lld:pubmed |
| pubmed-article:2846327 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2846327 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:2846327 | pubmed:volume | 154 | lld:pubmed |
| pubmed-article:2846327 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2846327 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2846327 | pubmed:pagination | 67-72 | lld:pubmed |
| pubmed-article:2846327 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:meshHeading | pubmed-meshheading:2846327-... | lld:pubmed |
| pubmed-article:2846327 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2846327 | pubmed:articleTitle | Chronic tranylcypromine treatment induces functional alpha 2-adrenoceptor down-regulation in rats. | lld:pubmed |
| pubmed-article:2846327 | pubmed:affiliation | Department of Psychiatry, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada. | lld:pubmed |
| pubmed-article:2846327 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2846327 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2846327 | lld:pubmed |
